Exendin-4 Improves Reversal of Diabetes in NOD Mice Treated with Anti-CD3 Monoclonal Antibody by Enhancing Recovery of β-Cells
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Immune modulators can arrest loss of insulin secretion in type 1 diabetes mellitus (T1DM), but they have not caused permanent disease remission or restored normal insulin secretion. We tested whether exendin-4, a glucagon-like peptide-1 receptor agonist, would enhance remission of T1DM in NOD mice treated with anti-CD3 monoclonal antibody (mAb) and studied the effects of exendin-4 treatment on cellular and metabolic responses of β-cells. Diabetic NOD mice treated with anti-CD3 mAb and exendin-4 had a higher rate of remission (44%) than mice treated with anti-CD3 mAb alone (37%) or exendin-4 (0%) or insulin or IgG alone (0%) (P < 0.01). The effect of exendin-4 on reversal of diabetes after anti-CD3 mAb was greatest in mice with a glucose level of less than 350 mg/dl at diagnosis (63 vs. 39%, P < 0.05). Exendin-4 did not affect β-cell area, replication, or apoptosis or reduce the frequency of diabetogenic or regulatory T cells or modulate the antigenicity of islet cells. Reversal of T1DM with anti-CD3 mAb was associated with recovery of insulin in glucose transporter-2+/insulin− islet cells that were identified at diagnosis. Glucose tolerance and insulin responses improved in mice treated with combination therapy, and exendin-4 increased insulin content and insulin release from β-cells. We conclude that treatment with glucagon-like peptide-1 receptor agonist enhances remission of T1DM in NOD mice treated with anti-CD3 mAb by enhancing the recovery of the residual islets. This combinatorial approach may be useful in treatment of patients with new-onset T1DM.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies to date that have reported an increase in β-cell mass with glucagon-like peptide 1 (GLP-1)-1 based therapies were undertaken in young rodents (17–21).”
From Age-Dependent Decline in β-Cell Proliferation Restricts the Capacity of β-Cell Regeneration in Mice (2009) · cites this paper as [20]
Citations
Cites
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus
Herold, K. C., Hagopian, W., Auger, J. A., Poumian-Ruiz, E., Taylor, L., Donaldson, D., Gitelman, S. E., Harlan, D. M., Xu, D., Zivin, R. A., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012864 · Cited by 1,222
Self-citationXu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes
Keymeulen, B., Vandemeulebroucke, E., Ziegler, A. G., Mathieu, C., Kaufman, L., Hale, G., Gorus, F., Goldman, M., Walter, M., Candon, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043980 · Cited by 1,099 · cited 2×
“In the European study, the clinical response to drug treatment was most apparent in those subjects in whom the magnitude of the Cpeptide response to a glucose clamp at diagnosis was in the upper half of C-peptide responses of all subjects at diagnosis (3).”
BackgroundAnti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice.
Chatenoud, L., Thervet, E., Primo, J., & Bach, J. F. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.1.123 · Cited by 664 · cited 2×
“(32) and recently reported by our group (18, 31).”
BackgroundFarilla, L., Bulotta, A., Hirshberg, B., Li Calzi, S., Khoury, N., Noushmehr, H., Bertolotto, C., Di Mario, U., Harlan, D. M., & Perfetti, R. (2003) · Endocrinology · doi:10.1210/en.2003-0323 · Cited by 664
Herold, K. C., Gitelman, S. E., Masharani, U., Hagopian, W., Bisikirska, B., Donaldson, D., Rother, K., Diamond, B., Harlan, D. M., & Bluestone, J. A. (2005) · Diabetes · doi:10.2337/diabetes.54.6.1763 · Cited by 634
Self-citationGlucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis
Li, Y., Hansotia, T., Yusta, B., Ris, F., Halban, P. A., & Drucker, D. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209423200 · Cited by 589
Belghith, M., Bluestone, J. A., Barriot, S., Mégret, J., Bach, J.-F., & Chatenoud, L. (2003) · Nature Medicine · doi:10.1038/nm924 · Cited by 586
Self-citationStoffers, D. A., Kieffer, T. J., Hussain, M. A., Drucker, D. J., Bonner-Weir, S., Habener, J. F., & Egan, J. M. (2000) · Diabetes · doi:10.2337/diabetes.49.5.741 · Cited by 576 · cited 2×
“075 g ip for 10 d, beginning at the onset of hyperglycemia (9, 10, 19).”
Background
Cited by
Items 101–169 of 169
Insulin Receptor Substrate-2 in β-Cells Decreases Diabetes in Nonobese Diabetic Mice
Norquay, L., D’Aquino, K. E., Opare-Addo, L., Kuznetsova, A., Haas, M., Bluestone, J. A., & White, M. F. (2009) · Endocrinology · doi:10.1210/en.2009-0395 · Cited by 22
Self-citationThe Tyrphostin Agent AG490 Prevents and Reverses Type 1 Diabetes in NOD Mice
Davoodi‐Semiromi, A., Wasserfall, C. H., Xia, C. Q., Cooper‐DeHoff, R. M., Wabitsch, M., Clare-Salzler, M. J., & Atkinson, M. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036079 · Cited by 21
Xue, S., Wasserfall, C. H., Parker, M., McGrail, S., MCGRAIL, K. M., Campbell‐Thompson, M., Schatz, D., Atkinson, M. A., & Haller, M. J. (2009) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2008.12.004 · Cited by 20
Challenges in developing endpoints for type 1 diabetes intervention studies
Cernea, S., Raz, I., Herold, K. C., Hirshberg, B., Roep, B. O., Schatz, D., Fleming, G. A., Pozzilli, P., Little, R. R., Schloot, N. C., et al. (2009) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1002 · Cited by 21
Self-citationGastrointestinal Tract and Endocrine System
Keil, C., Jäckel, E., Manns, M. P., & Bachmann, O. P. (2016) · Springer eBooks · doi:10.1007/978-3-319-28386-9_6 · Cited by 19
The role of incretin-based therapies in prediabetes: A review
Ahmadieh, H., & Azar, S. T. (2014) · Primary care diabetes · doi:10.1016/j.pcd.2014.02.005 · Cited by 24
GABAB-Receptor Agonist-Based Immunotherapy for Type 1 Diabetes in NOD Mice
Tian, J., Middleton, B., Lee, V. S., Park, H. W., Zhang, Z., Kim, B.-K., Lowe, C., Nguyen, N., Liu, H., Beyer, R. S., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9010043 · Cited by 19
Advances in Type 1 Diabetes Therapeutics: Immunomodulation and β-Cell Salvage
Waldron-Lynch, F., & Herold, K. C. (2009) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2009.01.005 · Cited by 24
“Not surprisingly, the effects of treatment were greatest in mice with the largest residual b-cell mass.(102) These results provide”
BackgroundSelf-citationEfforts to Prevent and Halt Autoimmune Beta Cell Destruction
Haller, M. J., Atkinson, M. A., & Schatz, D. (2010) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2010.05.006 · Cited by 18
Possible Role of GLP-1 and Its Agonists in the Treatment of Type 1 Diabetes Mellitus
Issa, C. M., & Azar, S. T. (2012) · Current Diabetes Reports · doi:10.1007/s11892-012-0291-6 · Cited by 15
Noninsulin pharmacological management of type 1 diabetes mellitus
Garg, V. (2011) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.83053 · Cited by 21
“Both in vitro studies and animal models of non-autoimmune diabetes have shown that incretin-based agents have the potential to expand beta-cell mass, stimulation of islet neogenesis and betacell proliferation, differentiation of putative beta-cell precursors, and inhibition of beta-cell apoptosis.[40]”
BackgroundDurana, Y. D. D., Lau, J., Knee, D. A., Filippi, C. M., Londei, M., McNamara, P., Nasoff, M. S., DiDonato, M., Glynne, R. J., & Herman, A. E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078483 · Cited by 16
“In addition, we identified 33% of islet cells as insulin-/glucagon-/Pdx1+ cells (Figure 5b, arrowheads, and Figure S6e-h, m), which may represent degranulated beta cells, as previously described [14].”
BackgroundResultInfluentialProgress towards the clinical use of CD3 monoclonal antibodies in the treatment of autoimmunity
Chatenoud, L. (2009) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0b013e32832ce95a · Cited by 15
Immunotherapies in Diabetes Mellitus Type 1
Gupta, S. (2012) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.04.008 · Cited by 15
Combination Therapies for Type 1 Diabetes: Why Not Now?
von Herrath, M. (2010) · Immunotherapy · doi:10.2217/imt.10.23 · Cited by 15
Treatment of diabetes with glucagon-like peptide-1 gene therapy
Riedel, M. J., & Kieffer, T. J. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.532786 · Cited by 14
Emerging immune therapies in type 1 diabetes and pancreatic islet transplantation
Schneider, D., Kretowicz, A., & von Herrath, M. G. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12046 · Cited by 14
“Exendin-4, a glucagon-like peptide-1 receptor agonist, enhances remission of diabetes in NOD mice treated with anti-CD3 mAb, most probably by enhancing residual islet recovery [79].”
BackgroundAntigen-based vs. systemic immunomodulation in type 1 diabetes: The pros and cons
Robert, S., Korf, H., Gysemans, C. A., & Mathieu, C. (2013) · Islets · doi:10.4161/isl.24785 · Cited by 16
Ludwig, B., Barthel, A., Reichel, A., Block, N. L., Ludwig, S., Schally, A. V., & Bornstein, S. R. (2014) · Vitamins and hormones · doi:10.1016/b978-0-12-800174-5.00008-9 · Cited by 13
“Further, several combinations of different immu- nomodulatory agents together or with agents improving beta cell function (e.g., anti-CD3þ insulin peptide; anti-CD3þexenatide, mycophenolate mofetilþ anti-CD25 (daclizumab); rapamycin (sirolimus)þ interleukin-10 rapamycin (sirolimus)þ interleukin-2) are currently under…”
From pumps to prevention: recent advances in the treatment of type 1 diabetes
Sherr, J. L., Cengiz, E., & Tamborlane, W. V. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.06.011 · Cited by 16
Gautier, A., Roussel, R., Lange, C., Piguel, X., Cauchi, S., Vol, S., Froguel, P., Balkau, B., & Bonnet, F. (2011) · Diabetes · doi:10.2337/db10-1442 · Cited by 13
Use of Glucagon-Like Peptide-1 Agonists to Improve Islet Graft Performance
Wang, Y., Qi, M., McGarrigle, J. J., Rady, B., Davis, M., Vaca, P., & Oberholzer, J. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0402-z · Cited by 15
“These studies have several following important findings: GLP-1 can enhance remission of T1DM in NOD mice treated with anti-CD3 mAb by increasing the recovery of the residual islet mass [42].”
Vildagliptin/pioglitazone combination improved the overall glycemic control in type I diabetic rats
Abdelhamid, A. M., Abdelaziz, R. R., & Salem, H. A. (2018) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2017-0680 · Cited by 11
Influence of catch-up growth on islet function and possible mechanisms in rats
Chen, L., Yang, W.-H., Zheng, J., Zhang, J., & Yue, L. (2011) · Nutrition · doi:10.1016/j.nut.2010.09.007 · Cited by 10
Kuznetsova, A., Yu, Y., Hollister‐Lock, J., Opare-Addo, L., Rozzo, A., Sadagurski, M., Norquay, L., Reed, J. E., Khattabi, I. E., Bonner‐Weir, S., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.80749 · Cited by 10
Cheng, L., Zhang, L., Qiao, L., Hu, S., Ge, J., Hu, C., & Tang, L. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117985 · Cited by 9
Cari, L., Montanucci, P., Basta, G., Petrillo, M. G., Ricci, E., Pescara, T., Greco, A., Cipriani, S., Shimizu, J., Migliorati, G., et al. (2020) · Diabetes · doi:10.2337/db19-0087 · Cited by 8
Restoring immune balance in type 1 diabetes
Herold, K. C. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70123-2 · Cited by 9
Self-citationGlucagon-Like Peptide 1 and Type 1 Diabetes: NOD Ready for Prime Time?
Hadjiyanni, I., & Drucker, D. J. (2007) · Endocrinology · doi:10.1210/en.2007-1112 · Cited by 8
Serum Levels of Incretin Hormones – GLP-1 and GIP in Patients with Type 1 Diabetes Mellitus
Stanchev, P. E., Orbetzova, M. M., Terzieva, D. D., Davcheva, D. M., Iliev, D. A., Petrov, S. V., Koleva, D. I., & Nonchev, B. (2019) · Folia Medica · doi:10.2478/folmed-2018-0056 · Cited by 7
Gastrointestinal Tract and Endocrine System
Mpofu, N., Klose, M. A., Jäckel, E., Manns, M. P., & Bachmann, O. P. (2013) · Springer eBooks · doi:10.1007/978-94-007-5690-8_39 · Cited by 7
Use of GLP-1 Receptor Agonists for the Management of Type 1 Diabetes: A Pediatric Perspective
Nevo-Shenker, M., & Shalitin, S. (2024) · Hormone Research in Paediatrics · doi:10.1159/000541228 · Cited by 9
“In addition, studies in NOD mice have shown that GLP-1 RA administered in combination with various immunomodulatory agents, including anti-CD3 compounds [67], were more ef fi cient in inducing diabetes remission than when given as monotherapy [68].”
Zhao, R., Su, Z., Gu, J., Zhao, H., Bian, L., Yin, J., Cai, Y., Yang, T., Gu, Y., & Xu, X. (2025) · BMC Medicine · doi:10.1186/s12916-025-04001-5 · Cited by 6
Incorporating Type 1 Diabetes Prevention Into Clinical Practice
Gregory, J. M., Lilley, J. S., Misfeldt, A. A., Buscariollo, D. L., Russell, W. E., & Moore, D. J. (2010) · Clinical Diabetes · doi:10.2337/diaclin.28.2.61 · Cited by 6
Gao, H., Zhao, Q., Tang, S., Li, K., Qin, F., Song, Z., Pan, Y., Jin, L., & Zhang, Y. (2021) · Scientific Reports · doi:10.1038/s41598-021-83201-4 · Cited by 5
Reddy, S., Cheung, C. C. H., Chai, R. C. C., & Rodrigues, J. A. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1447.010 · Cited by 5
Seelig, E., Trinh, B., Hanssen, H., Schmidt‐Trucksäss, A., Ellingsgaard, H., Christ‐Crain, M., & Donath, M. Y. (2019) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.75 · Cited by 4
Exendin-4 Exacerbates Burn-Induced Morbidity in Mice by Activation of the Sympathetic Nervous System
Ji, X.-J., Hao, J.-W., Li, G., Dong, N., Wang, X., Zhou, M., Zhang, Q., & Yao, Y.-M. (2019) · Mediators of Inflammation · doi:10.1155/2019/2750528 · Cited by 5
“Moreover, it could reduce the frequency of regulatory T cells (Tregs) in the thymus [13, 18], but it could increase in the spleen with a trend of enhanced suppression ability [19].”
BackgroundUpdate on Global Intervention Studies in Type 1 Diabetes
Chiang, J. L., Haller, M. J., & Schatz, D. (2012) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2012.07.003 · Cited by 4
Next-gen therapeutics to spare and expand beta-cell mass
Bolla, A. M., Usuelli, V., Nasr, M. B., Frigerio, S., Loretelli, C., D’Addio, F., & Fiorina, P. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.09.001 · Cited by 3
A study on the role of genes of innate immunity in type 1 diabetes
Sedimbi, S. K. (2010) · Figshare · Cited by 3
Attacking the source: anti-PDX-1 responses in type 1 diabetes
Lightfoot, Y. L., & Mathews, C. E. (2009) · Laboratory Investigation · doi:10.1038/labinvest.2009.121 · Cited by 2
Faria, A. L. D. D. S., Dias, M. A., Leme, V. B., Mayoral, É. E., da Silva, R. E., Mâncio, R. D., Ferreira, R. S., & Caldeira, E. J. (2012) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2012.09.015 · Cited by 2
“Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus.”
BackgroundChatzicharalampous, C., Bai, D., Camp, O. G., Joshi, N., & Abu‐Soud, H. M. (2022) · Advances in Redox Research · doi:10.1016/j.arres.2022.100032 · Cited by 2
Anti-lymphocyte antibody-based immunotherapy in type 1 diabetes
Xia, C., Liu, Y.-T., Guan, Q., & Clare-Salzler, M. J. (2013) · Chinese Medical Journal · doi:10.3760/cma.j.issn.0366-6999.20122444 · Cited by 2
Autoantigen-Specific Immunotherapy
Han, S., Donelan, W., Reeves, W. H., & Yang, L.-J. (2011) · InTech eBooks · doi:10.5772/24479 · Cited by 2
Prevention of β-Cell Destruction in Autoimmune Diabetes: Current Approaches and Future Prospects
Sedimbi, S. K., & Sanjeevi, C. B. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-90-481-3271-3_26 · Cited by 2
Dubala, A., Gupta, A., & Samanta, M. K. (2014) · Medical Hypotheses · doi:10.1016/j.mehy.2014.04.023 · Cited by 2
“[52] divulged the efficacy of exendin-4 in combination with CD3 mAbs in NOD mice, which showed improved b-cell mass, and subsequent increase in insulin secretion.”
BackgroundAskenasy, N. (2015) · International Reviews of Immunology · doi:10.3109/08830185.2015.1010723 · Cited by 2
“A series of studies have reported superior results by combination of ALS and anti-CD3 antibodies with exendin-4 [109, 110], an agent involved in humoral and cellular immune responses that also promotes differentiation and regeneration of β-cells [111].”
ResultAn overview of non-insulin adjunctive therapies for Type 1 diabetes
Ballav, C., & Gough, S. C. L. (2014) · Diabetes Management · doi:10.2217/dmt.14.38 · Cited by 2
Reestablishing T Cell Tolerance by Antibody-Based Therapy in Type 1 Diabetes
Morillon, Y. M., Martin, A. J., Gojanovich, G. S., Wang, B., & Tisch, R. (2015) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-015-0336-z · Cited by 2
Immunotherapy of Type-1 Diabetes: Immunoprevention and Immunoreversal
Waldron-Lynch, F., & Herold, K. C. (2010) · Humana Press eBooks · doi:10.1007/978-1-60327-478-4_18 · Cited by 2
Self-citationGLP-1R is downregulated in beta cells of NOD mice and T1D patientsPreprint
Recino, A., Barkan, K., Schmidt-Christensen, A., Nilsson, J., Holmes, N., Howie, D., Holmberg, D., Larsson, P. G., Flodström‐Tullberg, M., Laraia, L., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/845776 · Cited by 2
“also failed to achieve remission in mice (19) and humans (22), and the contribution of GLP1R stimulation has been unclear.”
BackgroundWang, Y., He, S., Yang, H., Zhang, J., Yu, L., Xiong, J., Li, X., Qiu, J., & Ma, B. (2026) · Biology · doi:10.3390/biology15171472 · Cited by 1
“Several studies have investigated combination strategies such as exendin-4 with anti-CD3 monoclonal antibody [13], and liraglutide with anti-IL-21 monoclonal antibody [14], which showed significant therapeutic effects, and other combinations have also shown promising results [15,16].”
Antibody-Based and and Cellular Therapies of Type 1 Diabetes
Xia, C., Liu, Y.-T., Guan, Q., & Clare-Salzler, M. J. (2013) · InTech eBooks · doi:10.5772/53495 · Cited by 1
“For this purpose, combinatorial therapy is a rational approach [54, 55].”
BackgroundBiologic therapies in type 1 diabetes: how far are they from us?
Deng, C., Xiang, Y., & Zhou, Z. (2013) · Chinese Medical Journal · doi:10.3760/cma.j.issn.0366-6999.20132375 · Cited by 1
“Exenatide improved reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of β cells.(25) Along these lines, a pilot trial in children and adolescents with T1D using GAD-alum (Diamyd) in combination with vitamin D and ibuprofen is recruiting participants (NCT01785108).”
BackgroundLee, M., & Kim, K. (2009) · Journal of Korean Medical Association · doi:10.5124/jkma.2009.52.7.677
Sanjeevi, C. B., & Sun, C. (2014) · Springer eBooks · doi:10.1007/978-94-007-6686-0_19
Prolactin as an Adjunct to Anti-CD3 Type I Diabetes Therapy
Hyslop, C. M. (2014) · Libraries and Cultural Resources (University of Calgary) · doi:10.11575/prism/27455
Interferon alpha and type 1 diabetes mellitus
Ramírez, A. C., Marin, Y. R., & Rivero, I. B. (2013) · Revista cubana de endocrinología
Immunotherapy and T Cell Receptor Analysis in Recurrent Type 1 Diabetes
Garland, A. L. (2019) · ProQuest Demo Repository · doi:10.17615/5pst-j283
Casiraghi, F. (2014) · Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) · doi:10.13130/casiraghi-francesca_phd2014-03-11
“Antidiabetogenic effect of glucagonlike peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus.”
BackgroundLim, G. E. (2010) · TSpace (University of Toronto) · Cited by 1
Type 1 Diabetes: Past, Present, and Future Therapies
Singh, P., Kokil, G. R., Tupally, K. R., Poddar, K., Tan, A., Venkatesan, T., Parekh, H. S., & Pastorin, G. (2016) · SpringerBriefs in applied sciences and technology · doi:10.1007/978-981-10-0602-9_4
Arruebarrena, J. R. N. (2009) · DOAJ (DOAJ: Directory of Open Access Journals)
Sanjeevi, C. B., & Sun, C. (2014) · Springer eBooks · doi:10.1007/978-94-007-6884-0_19-2
Glucagon Like Peptide-1: More than Glucose Control and Weight ReductionPreprint
Chen, Y., Shao, S., Zhang, X., Xu, Q., & Pan, R. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4161722
Tondello, C. (2024) · Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) · doi:10.21248/gups.83267
Metadata
- Authors
- Sherry, N. A., Chen, W., Kushner, J. A., Glandt, M., Tang, Q., Tsai, S., Santamaria, P., Bluestone, J. A., Brillantes, A.-M. B., & Herold, K. C.
- Affiliations
- Columbia University Irving Medical Center (US)
- Yale University (US)
- Children's Hospital of Philadelphia (US)
- University of California, San Francisco (US)
- University of Calgary (CA)
- Julia McFarlane Diabetes Research Centre and Department of Microbiology and Infectious Diseases (S.T., P.S.), University of Calgary, Calgary, Alberta, Canada T2N 1N4
- Corresponding author
- Herold, Kevan C.
- ORCID
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2007-11-01
- Volume
- 148
- Issue
- 11
- Pages
- 5136-5144
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W1983796537
- Cited by
- 169
- References
- 34
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 4 · 2022: 4 · 2021: 5 · 2020: 6 · 2019: 7 · 2018: 4 · 2017: 5 · 2016: 9 · 2015: 7 · 2014: 13 · 2013: 19 · 2012: 16
- FWCI
- 10.39
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pediatric Endocrine Society
- Alberta Heritage Foundation for Medical Research
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases (AI98-010)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK 57846, DK068678, K08DK064101, R01DK068678, P30DK063608, R01DK057846)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- exendin-4, GLP-1 receptor agonists, type 1 diabetes, diabetes remission, anti-CD3 monoclonal antibody, beta-cell recovery, NOD mice, insulin secretion, GLUT2, immunomodulation, combination therapy
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Exenatide, Animals, Antibodies, Monoclonal, Cells, Cultured, Combined Modality Therapy, Diabetes Mellitus, Type 1, Female, Immunotherapy, Peptides, Remission Induction, Venoms, Mice, SCID, Mice, Inbred NOD, CD3 Complex, Receptors, Glucagon, Insulin-Secreting Cells, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.